UVA Tracking #
HSR190094
Principal Investigator
Michael Devitt
Contact
Milos Lesevic
Contact Email
Contact Phone
434.243.0544
Official Trial Title
An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Study Description
The UVA Cancer Center seeks adults ages 18 and over with previously untreated metastatic urothelial (bladder) cancer for a clinical trial. The purpose of this study is to evaluate a combination of 2 drugs vs standard chemotherapy in patients with metastatic urothelial cancer. Disease response and good and bad effects of the drug will be studied as part of this study. Study specific tests will be provided at no cost to you.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04223856
Compensation
Compensation: $50 per visit. Reimbursement: Up to $175 for hotel stay.